Feb 28, 2023
Sage Therapeutics Receives EU Orphan Drug Designation for Huntington's Disease Treatment Candidate Sage Therapeutics declared the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is developing as a potential oral therapy for cognitive disor...
Read More...
May 27, 2019
The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA). SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN pro...
Read More...
May 06, 2019
SMA (Spinal Muscular Atrophy) - a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or breathing. Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028). ...
Read More...
Apr 29, 2019
Spinal muscular atrophy (SMA) being a rare genetic neuromuscular disorder results in progressive muscle weakness and atrophy. It affects the part of the nervous system that controls voluntary muscle movement. Spinal Muscular Atrophy Current therapeutic management revolves around supportive and multidisciplinary car...
Read More...
Apr 26, 2019
Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons in the Spinal Cord. SMA is one of the most common causes of infant mortality and mobility impairment. Spinal Muscular A...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper